96401

Chemotherapy administration, subcutaneous or intramuscular; non-hormonal anti-neoplastic

CPT code 96401 describes the administration of non-hormonal anti-neoplastic chemotherapy or other highly complex drugs via subcutaneous or intramuscular injection. This procedure is distinguished from standard therapeutic injections (CPT 96372) by the inherent complexity of the agents involved, which often require specialized training for handling, preparation, and administration, as well as intensified patient monitoring for immediate toxicities or hypersensitivity reactions. These medications are typically hazardous materials that necessitate strict adherence to safety protocols, including the use of personal protective equipment (PPE) and specific disposal techniques for biohazardous and chemotherapeutic waste. The clinical process begins with a comprehensive review of the patient's medical record, including current laboratory values such as complete blood counts and metabolic panels to ensure the patient can safely receive the treatment. The clinician must verify the medication against the physician's order, ensuring the correct dosage is prepared, often involving double-verification by two licensed healthcare professionals. The injection site is selected based on the specific medication's pharmacokinetics and patient comfort, then prepared with an antiseptic agent. Following the administration of the drug, the patient is monitored for a period for signs of anaphylaxis or other adverse events. Documentation of the procedure must include the drug name, dosage, route of administration, the specific site of the injection, and the patient's tolerance. It is important to note that while 96401 is used for non-hormonal anti-neoplastics, its use also extends to certain monoclonal antibodies and biological response modifiers that carry similar levels of risk and complexity as traditional chemotherapy. Proper reporting requires understanding the distinction between hormonal and non-hormonal agents, as well as the unique risks associated with biologics.

Clinical Indications

  • Treatment of primary malignant neoplasms
  • Treatment of metastatic cancer
  • Administration of non-hormonal monoclonal antibodies
  • Administration of complex biological response modifiers
  • Adjuvant chemotherapy following surgical intervention
  • Palliative care for symptom management in advanced cancer
  • Treatment of specific autoimmune disorders requiring high-complexity anti-neoplastic agents

Procedure Steps

  1. Perform pre-administration clinical assessment and verify laboratory results.
  2. Identify the patient using two identifiers and explain the procedure and side effects.
  3. Verify the medication order, drug name, dosage, and route (SC or IM).
  4. Utilize PPE and follow hazardous drug handling protocols for preparation.
  5. Select and cleanse the injection site with an appropriate antiseptic.
  6. Administer the non-hormonal anti-neoplastic agent subcutaneously or intramuscularly.
  7. Dispose of all contaminated sharps and materials in designated chemotherapy waste containers.
  8. Monitor the patient for immediate adverse reactions or hypersensitivity for a clinically appropriate duration.
  9. Document the procedure including site, drug, dosage, and patient tolerance in the medical record.

Coding Guidelines

  • Report 96401 for non-hormonal anti-neoplastic injections only.
  • Use 96402 for hormonal anti-neoplastic injections such as leuprolide.
  • The supply of the drug/agent is billed separately using the appropriate HCPCS J-code.
  • Do not report 96401 in conjunction with 96372 for the same injection.
  • If a significant, separately identifiable E/M service is performed, append modifier 25 to the E/M code.
  • Coding should reflect the complexity of the drug rather than just the route of administration; certain monoclonal antibodies qualify for 96401.
  • Local anesthesia and standard supplies are included in the administration code and should not be reported separately.

Associated ICD-10 Codes